Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
null nullAnthony C GordonPaul R MounceyFarah Al-BeidhKathryn M RowanAlistair D NicholYaseen M ArabiDjillali AnnaneAbigail BeaneWilma van Bentum-PuijkLindsay R BerryZahra BhimaniMarc J M BontenCharlotte Ann BradburyFrank M BrunkhorstAdrian BuzgauAllen C ChengMichelle A DetryEamon J DuffyLise J EstcourtMark FitzgeraldHerman GoossensRashan HaniffaAlisa M HigginsThomas E HillsChristopher M HorvatFrancois LamontagnePatrick R LawlerHelen L LeavisKelsey M LinstrumEdward LittonElizabeth LorenziJohn C MarshallFlorian B MayrDaniel F McAuleyAnna McGlothlinShay P McGuinnessBryan J McVerryStephanie K MontgomerySusan C MorpethSrinivas MurthyKatrina OrrRachael L ParkeJane C ParkerAsad E PatanwalaVille PettiläEmma RademakerMarlene S SantosChristina T SaundersChristopher W SeymourManu Shankar-HariWendy I SliglAlexis F TurgeonAnne M TurnerFrank L van de VeerdonkRyan ZarychanskiCameron GreenRoger J LewisDerek C AngusColin J McArthurScott BerrySteve A WebbLennie P G DerdePublished in: The New England journal of medicine (2021)
In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).